Clinical trial
A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors
NCT03375086 is registered in ClinicalTrials.gov with Apexian Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors
- Lead sponsor
- Apexian Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 30, 2018
- Completion date
- January 9, 2019
- Enrollment
- 19 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
cancer